Papers/CAERS:2018-CFS-000217
openFDA CAERS report 2018-CFS-000217
CON-CRETThe record
2 findings drawn from this paper, on 1 compound across 2 endpoints.
What it reported
How to read these marksWhat moved
2 findings
creatine — increases serum creatine kinase activity
PreliminaryGrade D, Preliminary. Non-human or in vitro only.Finding“CAERS report 2018-CFS-000217: Blood creatine phosphokinase increased following CON-CRET.”
Quoted verbatim from openFDA CAERS report 2018-CFS-000217. - Study
- spontaneous report · not in humans
- Population
- not applicable — single spontaneous report, no defined population (age 29 year(s), Male)
openFDA CAERS report 2018-CFS-000217CAERS:2018-CFS-000217
creatine — increases serum creatinine concentration
PreliminaryGrade D, Preliminary. Non-human or in vitro only.Findingreplicated ×3“CAERS report 2018-CFS-000217: Blood creatinine increased following CON-CRET.”
Quoted verbatim from openFDA CAERS report 2018-CFS-000217. - Study
- spontaneous report · not in humans
- Population
- not applicable — single spontaneous report, no defined population (age 29 year(s), Male)
openFDA CAERS report 2018-CFS-000217CAERS:2018-CFS-000217